



## AC Immune to Participate in Upcoming Virtual Investor Conferences in September

September 2, 2021

LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in the following upcoming virtual investor conferences:

### **Citi's 16<sup>th</sup> Annual BioPharma Virtual Conference**

One-on-one meetings – Wednesday, September 8, 2021

### **Morgan Stanley's 19<sup>th</sup> Annual Global Healthcare Conference**

One-on-one meetings – Friday, September 10, 2021

### **H.C. Wainwright 23<sup>rd</sup> Annual Global Investment Conference**

Corporate presentation – On-demand starting on September 13, 2021

One-on-one meetings – Wednesday, September 15, 2021

During the conferences, Prof. Andrea Pfeifer, CEO, AC Immune SA, will discuss the Company's corporate strategy and precision medicine approach, while highlighting its clinical-stage vaccine programs targeting phospho-Tau, Abeta, and alpha-synuclein in neurodegenerative diseases as well as the recent [top-line data from Lauriet Phase 2 trial](#) evaluating semorinemab in mild-to-moderate AD.

A webcast of the corporate presentation will be available on the [Events Page](#) of AC Immune's website.

### **About AC Immune SA**

AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and NeuroOrphan indications driven by misfolded proteins. The Company's two clinically validated technology platforms, SupraAntigen<sup>®</sup> and Morphomer<sup>®</sup>, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >\$3 billion in potential milestone payments.

SupraAntigen<sup>®</sup> is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP and RU. Morphomer<sup>®</sup> is a registered trademark of AC Immune SA in CN, CH, GB, JP, and NO.

### **For further information, please contact:**

#### **Media Relations**

Saoyuth Nidh  
AC Immune  
Phone: +41 21 345 91 34  
Email: [saoyuth.nidh@acimmune.com](mailto:saoyuth.nidh@acimmune.com)

#### **Investor Relations**

Yves Kremer, Ph.D.  
AC Immune  
Phone: +41 21 345 91 90  
Email: [yves.kremer@acimmune.com](mailto:yves.kremer@acimmune.com)

#### **U.S. Media**

Katie Gallagher  
LaVoie Health Science  
Phone: +1 617 792 3937  
Email: [kgallagher@lavoiehealthscience.com](mailto:kgallagher@lavoiehealthscience.com)

#### **U.S. Investors**

Corey Davis, Ph.D.  
LifeSci Advisors  
Phone: +1 212 915 2577  
Email: [cdavis@lifesciadvisors.com](mailto:cdavis@lifesciadvisors.com)

### **Forward-looking statements**

This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information – Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.



Source: AC Immune SA